长期恩替卡韦治疗在欧洲人群的疗效和安全性。

StephenW

Minerva Gastroenterol Dietol. 2018 Jan 10. doi: 10.23736/S1121-421X.18.02470-4. [Epub ahead of print]
Efficacy and safety of long term entecavir therapy in a European population.Collo A1, Belci P1, Fagoonee S2, Loreti L1, Gariglio V1, Parise R1, Magistroni P1, Durazzo M3.
Author information
1Department of Medical Sciences, University of Turin, Turin, Italy.2Institute for Biostructures and Bioimages (CNR) c/o Molecular Biotechnology Center, Turin, Italy.3Department of Medical Sciences, University of Turin, Turin, Italy - [email protected].

AbstractBACKGROUND: Therapy in chronic hepatitis B (CHB) patients aims at improving their survival by preventing disease progression to cirrhosis and its complications. Entecavir (ETV) is currently a first line therapeutic agent recommended for the treatment of CHB. Our aim was to evaluate the long term outcome of a cohort of CHB patients treated with ETV.
METHODS: Thirty-four patients treated with ETV for at least 6 months were included in this study. The virologic response was determined by the dosage of serum HBV-DNA, HBsAg, HBeAg, anti-HBs and anti-HBe antibodies. Death, acute pancreatitis, lactic acidosis and kidney function impairment were considered as major adverse events.
RESULTS: The median period of treatment was 55 months (range 15-81). Thirty-three (97%) patients responded to the therapy after a mean time of 14.7 weeks (4-60); of these, 29 (85.3%) maintained the HBV-DNA negativity in serum, while 4 patients (11.8%) had a breakthrough. The remaining patient did not respond. Seroconversion to anti-HBs and anti-HBe was not observed, although 2 patients lost the e and the s antigen, respectively. Baseline alanine aminostransferase (ALT) levels in serum were altered in 18 patients (52.9%), and returned to normal levels during the follow-up, with a reduction of 87.7 IU/L (p <0,0001). A case (3.4%) of hepatocellular carcinoma was observed after 24 months. No major adverse events were recorded.
CONCLUSIONS: ETV is effective in suppressing viral replication as well as in normalizing serum ALT levels, without anti-HBs seroconversion. Finally, ETV is a safe drug, substantially free of major side effects.


PMID:29327822DOI:10.23736/S1121-421X.18.02470-4

StephenW

Minerva Gastroenterol Dietol。 2018年1月10日。doi：10.23736 / S1121-421X.18.02470-4。 [电子版提前打印]
长期恩替卡韦治疗在欧洲人群的疗效和安全性。
Collo A1，Belci P1，Fagoonee S2，Loreti L1，Gariglio V1，Parise R1，Magistroni P1，Durazzo M3。
作者信息

1
    意大利都灵都灵大学医学系。
2
    意大利都灵生物结构和生物影像研究所（C / O）分子生物技术中心。
3
    意大利都灵都灵大学医学科学系 - [email protected]。

抽象
背景：

慢性乙型肝炎（CHB）患者的治疗旨在通过预防疾病进展为肝硬化及其并发症来改善其存活。恩替卡韦（ETV）目前是推荐用于CHB治疗的一线治疗剂。我们的目标是评估治疗ETV的CHB患者的长期结果。
方法：

本研究包括34名接受ETV治疗至少6个月的患者。病毒学应答由血清HBV-DNA，HBsAg，HBeAg，抗-HBs和抗-HBe抗体的剂量决定。死亡，急性胰腺炎，乳酸酸中毒和肾功能损害被认为是主要的不良事件。
结果：

治疗的中位时间为55个月（范围15-81）。平均时间为14.7周（4-60）的患者中有33名（97％）患者对治疗有反应;其中29例（85.3％）维持血清HBV-DNA阴性，4例（11.8％）有突破。剩下的病人没有回应。没有观察到抗HBs和抗HBe的血清转化，尽管2名患者分别失去了e抗原和s抗原。血清基线丙氨酸氨基转移酶（ALT）水平在18例患者中改变（52.9％），在随访期间恢复到正常水平，降低了87.7 IU / L（p <0.0001）。 24个月后观察到肝细胞癌（3.4％）。没有记录重大不良事件。
结论：

ETV在抑制病毒复制以及正常化血清ALT水平方面是有效的，没有抗-HBs血清转化。最后，ETV是一种安全的药物，基本上没有主要副作用。

结论：
    29327822
DOI：
    10.23736 / S1121-421X.18.02470-4

小牡丹

好文章，言简意赅。希望猪肉粉条都知道

newchinabok

24个月后观察到肝细胞癌（3.4％

StephenW

回复 newchinabok 的帖子

一个非常小的样品（34名患者）.
肝细胞癌发生在一名患者中 (3.4%).
得出一个结论:有效, 安全,基本上没有主要副作用.

商业战士

这么小的样本，这么大的结论，这个医生是在水论文，凑篇数吗？

StephenW

回复 商业战士 的帖子

我同意, 小的样本,观察期短, 但结论可以.